Related Experiment Videos
Primary diffuse large cell lymphoma of the mandible
Manuel F Rosado1, Daniel Morgensztern, Michael Peleg
1Division of Hematology/Oncology, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center and Jackson Memorial Hospital, Miami, Florida, USA
Leukemia & Lymphoma
|August 5, 2004
Summary
Primary diffuse large cell lymphoma of the mandible is a rare cancer. This study reviews 44 cases, finding jaw swelling and pain are common symptoms, with a 60% 5-year survival rate.
Area of Science:
- Oncology
- Hematology
- Oral and Maxillofacial Surgery
Background:
- Primary diffuse large cell lymphoma (DLCL) of the mandible is a rare extranodal non-Hodgkin's lymphoma (NHL).
- Understanding its clinical presentation and treatment outcomes is crucial for improving patient care.
Observation:
- This study analyzed 4 cases from the institution and reviewed 40 previously reported cases.
- The median age of presentation was 51 years, with equal gender distribution.
- Common symptoms included jaw swelling (58%), pain (53%), and numbness (20%).
Findings:
- The lymphoma was typically diagnosed at stage IE, confined to the jaw.
- Despite 'numb chin syndrome' symptoms, central nervous system involvement at diagnosis was not reported.
- Treatment varied, but combined chemotherapy and radiotherapy yielded a 5-year survival rate of approximately 60%.
Implications:
- Optimal therapeutic strategies for mandibular DLCL require further investigation.
- Multi-center prospective clinical trials are essential to establish standardized treatment protocols.
- Early diagnosis and tailored treatment may improve survival rates for this rare lymphoma.